Home
User Profile

Selected publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
  1. Brauns T, Leblanc P, Gelfand JA, Poznanski M. Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine? Expert Rev Vaccines. 2015 Mar; 14(3):435-46.

    View in: PubMed

  2. Leblanc P, Moise L, Luza C, Chantaralawan K, Lezeau L, Yuan J, Field M, Richer D, Boyle C, Martin WD, Fishman JB, Berg EA, Baker D, Zeigler B, Mais DE, Taylor W, Coleman R, Warren HS, Gelfand JA, De Groot AS, Brauns T, Poznansky MC. VaxCelerate II: Rapid development of a self-assembling vaccine for Lassa fever. Hum Vaccin Immunother. 2014 Oct 3; 10(10):3022-38.

    View in: PubMed

  3. Kashiwagi S, Brauns T, Gelfand J, Poznansky MC. Laser vaccine adjuvants. Hum Vaccin Immunother. 2014 Jul; 10(7):1892-907.

    View in: PubMed

  4. Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin NH, Nguyen M, Jean-Mary G, Tong X, Uppal P, Korochkina S, Forbes B, Chen T, Righi E, Bronson R, Chen H, Orsulic S, Brauns T, Leblanc P, Scholler N, Dranoff G, Gelfand J, Poznansky MC. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol. 2014; 7:15.

    View in: PubMed

  5. Kashiwagi S, Yuan J, Forbes B, Hibert ML, Lee EL, Whicher L, Goudie C, Yang Y, Chen T, Edelblute B, Collette B, Edington L, Trussler J, Nezivar J, Leblanc P, Bronson R, Tsukada K, Suematsu M, Dover J, Brauns T, Gelfand J, Poznansky MC. Near-infrared laser adjuvant for influenza vaccine. PLoS One. 2013; 8(12):e82899.

    View in: PubMed

  6. Gelfand JA. Case 12-2013: a woman with pulmonary infiltrates and respiratory failure. N Engl J Med. 2013 Aug 8; 369(6):583-4.

    View in: PubMed

  7. Saavedra AP, Warth JA, Burke JF, Norton KJ, Gelfand JA. Increased dense erythrocytes in flame-burned patients. Clin Hemorheol Microcirc. 2013; 53(4):349-56.

    View in: PubMed

  8. Leblanc PR, Yuan J, Brauns T, Gelfand JA, Poznansky MC. Accelerated vaccine development against emerging infectious diseases. Hum Vaccin Immunother. 2012 Jul; 8(7):1010-2.

    View in: PubMed

  9. Chen X, Kim P, Farinelli B, Doukas A, Yun SH, Gelfand JA, Anderson RR, Wu MX. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS One. 2010; 5(10):e13776.

    View in: PubMed

  10. Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008 Feb 1; 46(3):370-6.

    View in: PubMed

  11. Stowell CP, Gelfand JA, Shepard JA, Kratz A. Case records of the Massachusetts General Hospital. Case 17-2007. A 25-year-old woman with relapsing fevers and recent onset of dyspnea. N Engl J Med. 2007 May 31; 356(22):2313-9.

    View in: PubMed

  12. Borggraefe I, Yuan J, Telford SR, Menon S, Hunter R, Shah S, Spielman A, Gelfand JA, Wortis HH, Vannier E. Babesia microti primarily invades mature erythrocytes in mice. Infect Immun. 2006 Jun; 74(6):3204-12.

    View in: PubMed

  13. Shnayderman M, Mansfield B, Yip P, Clark HA, Krebs MD, Cohen SJ, Zeskind JE, Ryan ET, Dorkin HL, Callahan MV, Stair TO, Gelfand JA, Gill CJ, Hitt B, Davis CE. Species-specific bacteria identification using differential mobility spectrometry and bioinformatics pattern recognition. Anal Chem. 2005 Sep 15; 77(18):5930-7.

    View in: PubMed

  14. Eichhorn JH, Brauns TA, Gelfand JA, Crothers BA, Wilbur DC. A novel automated screening and interpretation process for cervical cytology using the internet transmission of low-resolution images: a feasibility study. Cancer. 2005 Aug 25; 105(4):199-206.

    View in: PubMed

  15. Takabayashi T, Shimizu S, Clark BD, Beinborn M, Burke JF, Gelfand JA. Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells. Surgery. 2004 May; 135(5):544-54.

    View in: PubMed

  16. Vannier E, Borggraefe I, Telford SR, Menon S, Brauns T, Spielman A, Gelfand JA, Wortis HH. Age-associated decline in resistance to Babesia microti is genetically determined. J Infect Dis. 2004 May 1; 189(9):1721-8.

    View in: PubMed

  17. Gelfand JA, Callahan MV. Babesiosis: An Update on Epidemiology and Treatment. Curr Infect Dis Rep. 2003 Feb; 5(1):53-58.

    View in: PubMed

  18. Takabayashi T, Vannier E, Burke JF, Tompkins RG, Gelfand JA, Clark BD. Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis. 1998 Jun; 177(6):1622-8.

    View in: PubMed

  19. Gelfand JA, Callahan MV. Babesiosis. Curr Clin Top Infect Dis. 1998; 18:201-16.

    View in: PubMed

  20. Sant GR, Theoharides TC, Letourneau R, Gelfand J. Interstitial cystitis and bladder mastocytosis in a woman with chronic urticaria. Scand J Urol Nephrol. 1997 Oct; 31(5):497-500.

    View in: PubMed

  21. Aiura K, Clark BD, Dinarello CA, Margolis NH, Kaplanski G, Burke JF, Tompkins RG, Gelfand JA. Interaction with autologous platelets multiplies interleukin-1 and tumor necrosis factor production in mononuclear cells. J Infect Dis. 1997 Jan; 175(1):123-9.

    View in: PubMed

  22. Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, Gelfand JA. A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol. 1996 May 1; 156(9):3455-60.

    View in: PubMed

  23. Boustani MR, Gelfand JA. Babesiosis. Clin Infect Dis. 1996 Apr; 22(4):611-5.

    View in: PubMed

  24. Frautschi JR, Eberhart RC, Hubbell JA, Clark BD, Gelfand JA. Alkylation of cellulosic membranes results in reduced complement activation. J Biomater Sci Polym Ed. 1996; 7(8):707-14.

    View in: PubMed

  25. Ryan CM, Atkins MB, Mier JW, Gelfand JA, Tompkins RG. Effects of malignancy and interleukin-2 infusion on gut macromolecular permeability. Crit Care Med. 1995 Nov; 23(11):1801-6.

    View in: PubMed

  26. Mileno MD, Margolis NH, Clark BD, Dinarello CA, Burke JF, Gelfand JA. Coagulation of whole blood stimulates interleukin-1 beta gene expression. J Infect Dis. 1995 Jul; 172(1):308-11.

    View in: PubMed

  27. Harris BH, Gelfand JA. The immune response to trauma. Semin Pediatr Surg. 1995 May; 4(2):77-82.

    View in: PubMed

  28. Knox TA, Kaplan MM, Gelfand JA, Wolff SM. Methotrexate treatment of idiopathic granulomatous hepatitis. Ann Intern Med. 1995 Apr 15; 122(8):592-5.

    View in: PubMed

  29. Dirkes K, Harris BH, Connolly RJ, Schwaitzberg SD, Dinarello CA, Gelfand JA. Platelet activating factor-antagonist improves survival in experimental staphylococcal septicemia. J Pediatr Surg. 1994 Aug; 29(8):1055-7; discussion 1057-8.

    View in: PubMed

  30. Wakabayashi G, Cannon JG, Gelfand JA, Clark BD, Aiura K, Burke JF, Wolff SM, Dinarello CA. Altered interleukin-1 and tumor necrosis factor production and secretion during pyrogenic tolerance to LPS in rabbits. Am J Physiol. 1994 Jul; 267(1 Pt 2):R329-36.

    View in: PubMed

  31. Boustani MR, Lepore TJ, Gelfand JA, Lazarus DS. Acute respiratory failure in patients treated for babesiosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1689-91.

    View in: PubMed

  32. Mester M, Carter EA, Tompkins RG, Gelfand JA, Dinarello CA, Burke JF, Clark BD. Thermal injury induces very early production of interleukin-1 alpha in the rat by mechanisms other than endotoxemia. Surgery. 1994 May; 115(5):588-96.

    View in: PubMed

  33. Mandle R, Baron C, Roux E, Sundel R, Gelfand J, Aulak K, Davis AE, Rosen FS, Bing DH. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J Immunol. 1994 May 1; 152(9):4680-5.

    View in: PubMed

  34. Granowitz EV, Porat R, Gelfand JA, Wolff SM, Dinarello CA. Administration of low-dose endotoxin to healthy humans increases C5a binding to circulating neutrophils. J Infect Dis. 1994 Feb; 169(2):480-2.

    View in: PubMed

  35. Gelfand JA. Too little oxygen, too little interleukin-2: a link between hypoxemia and cellular immune dysfunction. Crit Care Med. 1994 Feb; 22(2):187-8.

    View in: PubMed

  36. Aiura K, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits. Infect Immun. 1993 Aug; 61(8):3342-50.

    View in: PubMed

  37. Mester M, Tompkins RG, Gelfand JA, Dinarello CA, Burke JF, Clark BD. Intestinal production of interleukin-1 alpha during endotoxemia in the mouse. J Surg Res. 1993 Jun; 54(6):584-91.

    View in: PubMed

  38. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood. 1993 May 15; 81(10):2492-5.

    View in: PubMed

  39. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993 Apr 14; 269(14):1829-35.

    View in: PubMed

  40. Shapiro L, Gelfand JA. Cytokines and sepsis: pathophysiology and therapy. New Horiz. 1993 Feb; 1(1):13-22.

    View in: PubMed

  41. Kaplan E, Dinarello CA, Wakabayashi G, Burke JF, Connolly RS, Gelfand JA. Interleukin-1 pretreatment protects against endotoxin-induced hypotension in rabbits: association with decreased tumor necrosis factor levels. J Infect Dis. 1993 Jan; 167(1):244-7.

    View in: PubMed

  42. Cannon JG, Friedberg JS, Gelfand JA, Tompkins RG, Burke JF, Dinarello CA. Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. Crit Care Med. 1992 Oct; 20(10):1414-9.

    View in: PubMed

  43. Ho JL, Badaró R, Schwartz A, Dinarello CA, Gelfand JA, Sobel J, Barral A, Netto MB, Carvalho EM, Reed SG, et al. Diminished in vitro production of interleukin-1 and tumor necrosis factor-alpha during acute visceral leishmaniasis and recovery after therapy. J Infect Dis. 1992 Jun; 165(6):1094-102.

    View in: PubMed

  44. Perala DG, Chapman RJ, Gelfand JA, Callahan MV, Adams DF, Lie T. Relative production of IL-1 beta and TNF alpha by mononuclear cells after exposure to dental implants. J Periodontol. 1992 May; 63(5):426-30.

    View in: PubMed

  45. Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P, Mier JW. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood. 1991 Nov 15; 78(10):2505-13.

    View in: PubMed

  46. Stylianos S, Wakabayashi G, Gelfand JA, Harris BH. Experimental hemorrhage and blunt trauma do not increase circulating tumor necrosis factor. J Trauma. 1991 Aug; 31(8):1063-7.

    View in: PubMed

  47. Wakabayashi G, Gelfand JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest. 1991 Jun; 87(6):1925-35.

    View in: PubMed

  48. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 1991 Mar 1; 5(3):338-43.

    View in: PubMed

  49. Morin M, Schindler R, Wakabayashi G, Daumy G, Dinarello CA, Gelfand JA. Picogram concentrations of endotoxin stimulate synthesis of IL-1 beta and TNF alpha by human peripheral blood mononuclear cells exposed to recombinant human C5a. Eur Cytokine Netw. 1991 Jan-Feb; 2(1):27-30.

    View in: PubMed

  50. Perala D, Chapman R, Gelfand J. Complement activation by dental implants. Int J Oral Maxillofac Implants. 1991; 6(2):136-41.

    View in: PubMed

  51. Schindler R, Gelfand JA, Dinarello CA. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood. 1990 Oct 15; 76(8):1631-8.

    View in: PubMed

  52. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, Endres S, Lonnemann G, Corsetti J, Chernow B, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990 Jan; 161(1):79-84.

    View in: PubMed

  53. Li JJ, Sanders RL, McAdam KP, Hales CA, Thompson BT, Gelfand JA, Burke JF. Impact of C-reactive protein (CRP) on surfactant function. J Trauma. 1989 Dec; 29(12):1690-7.

    View in: PubMed

  54. Drapkin MS, Wisch JS, Gelfand JA, Cannon JG, Dinarello CA. Plasmapheresis for fulminant meningococcemia. Pediatr Infect Dis J. 1989 Jun; 8(6):399-400.

    View in: PubMed

  55. Li JJ, Sanders RL, McAdam KP, Gelfand JA, Burke JF. Endotoxin suppresses surfactant synthesis in cultured rat lung cells. J Trauma. 1989 Feb; 29(2):180-8.

    View in: PubMed

  56. Dinarello CA, Okusawa S, Gelfand JA. Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of ibuprofen. Prog Clin Biol Res. 1989; 299:203-15.

    View in: PubMed

  57. Kaplan E, Dinarello CA, Gelfand JA. Interleukin-1 and the response to injury. Immunol Res. 1989; 8(2):118-29.

    View in: PubMed

  58. Dinarello CA, Okusawa S, Gelfand JA. Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. Prog Clin Biol Res. 1989; 286:243-63.

    View in: PubMed

  59. Tredget EE, Yu YM, Zhong S, Burini R, Okusawa S, Gelfand JA, Dinarello CA, Young VR, Burke JF. Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits. Am J Physiol. 1988 Dec; 255(6 Pt 1):E760-8.

    View in: PubMed

  60. Vachino G, Heck LW, Gelfand JA, Kaplan MM, Burke JF, Berninger RW, McAdam KP. Inhibition of human neutrophil and Pseudomonas elastases by the amyloid P-component: a constituent of elastic fibers and amyloid deposits. J Leukoc Biol. 1988 Dec; 44(6):529-34.

    View in: PubMed

  61. Okusawa S, Yancey KB, van der Meer JW, Endres S, Lonnemann G, Hefter K, Frank MM, Burke JF, Dinarello CA, Gelfand JA. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med. 1988 Jul 1; 168(1):443-8.

    View in: PubMed

  62. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988 Apr; 81(4):1162-72.

    View in: PubMed

  63. van der Meer JW, Endres S, Lonnemann G, Cannon JG, Ikejima T, Okusawa S, Gelfand JA, Dinarello CA. Concentrations of immunoreactive human tumor necrosis factor alpha produced by human mononuclear cells in vitro. J Leukoc Biol. 1988 Mar; 43(3):216-23.

    View in: PubMed

  64. Okusawa S, Dinarello CA, Yancey KB, Endres S, Lawley TJ, Frank MM, Burke JF, Gelfand JA. C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-gamma. J Immunol. 1987 Oct 15; 139(8):2635-40.

    View in: PubMed

  65. Yamada Y, Hefter K, Burke JF, Gelfand JA. An in vitro model of the wound microenvironment: local phagocytic cell abnormalities associated with in situ complement activation. J Infect Dis. 1987 May; 155(5):998-1004.

    View in: PubMed

  66. Simon GL, Gelfand JA, Connolly RA, O'Donnell TF, Gorbach SL. Experimental Bacteroides fragilis bacteremia in a primate model: evidence that Bacteroides fragilis does not promote the septic shock syndrome. J Trauma. 1985 Dec; 25(12):1156-62.

    View in: PubMed

  67. Gelfand JA. How do complement components and fragments affect cellular immunological function? J Trauma. 1984 Sep; 24(9 Suppl):S118-24.

    View in: PubMed

  68. Gelfand JA, Donelan M, Burke JF. Preferential activation and depletion of the alternative complement pathway by burn injury. Ann Surg. 1983 Jul; 198(1):58-62.

    View in: PubMed

  69. Gelfand JA. Exploiting sex for therapeutic purposes. N Engl J Med. 1983 Jun 9; 308(23):1417-9.

    View in: PubMed

  70. Gelfand JA, Donelan M, Hawiger A, Burke JF. Alternative complement pathway activation increases mortality in a model of burn injury in mice. J Clin Invest. 1982 Dec; 70(6):1170-6.

    View in: PubMed

  71. Joiner KA, Hawiger A, Gelfand JA. Activation of the alternative complement pathway by blood culture isolates of Bacteroides fragilis. Infect Immun. 1981 Oct; 34(1):303-5.

    View in: PubMed

  72. Joiner KA, Gelfand JA, Onderdonk AB, Bartlett JG, Gorbach SL. Host factors in the formation of abscesses. J Infect Dis. 1980 Jul; 142(1):40-9.

    View in: PubMed

  73. Gadek JE, Hosea SW, Gelfand JA, Santaella M, Wickerhauser M, Triantaphyllopoulos DC, Frank MM. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med. 1980 Mar 6; 302(10):542-6.

    View in: PubMed

  74. Joiner KA, Shahon R, Gelfand JA. A sensitive microassay for the murine alternative complement pathway. J Immunol Methods. 1979; 31(3-4):283-90.

    View in: PubMed

  75. Gelfand JA, Hurley DL, Fauci AS, Frank MM. Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis. 1978 Jul; 138(1):9-16.

    View in: PubMed

  76. Frank M, Gelfand JA, Alling DW, Sherins RJ. Epsilon aminocaproic acid for hereditary angioedema. N Engl J Med. 1977 May 26; 296(21):1235-6.

    View in: PubMed

  77. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976 Dec 23; 295(26):1444-8.

    View in: PubMed

  78. Gelfand JA, Elin RJ, Berry FW, Frank MM. Endotoxemia associated with the Jarisch-Herxheimer reaction. N Engl J Med. 1976 Jul 22; 295(4):211-3.

    View in: PubMed

  79. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976 May; 84(5):580-93.

    View in: PubMed